This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Relation to Stage and Disease Course in North American Patients With Nasopharyngeal Carcinoma

H. Bryan Neel, III, MD, PhD; Gary R. Pearson, PhD; William F. Taylor, PhD

Arch Otolaryngol. 1984;110(11):742-747.

Abstract
• A prospective study of North American patients, mostly white, with different histopathologic types of nasopharyngeal carcinoma was initiated approximately five years ago. Several anti-Epstein-Barr virus (EBV) serologic tests are being evaluated; one is the antibody-dependent cellular cytotoxicity (ADCC) assay, which measures antibodies to an EBV-induced membrane antigen component. A low ADCC titer at diagnosis reflects a poor prognosis, and the determination of antibody titers by this assay identifies patients in whom recurrent disease is likely to develop after conventional radiation therapy for World Health Organization types 2 and 3 carcinomas. Of the patients who had high ADCC titers at diagnosis, 80% survived three years or longer, whereas 50% of the patients with low titers survived three years, and only 35% survived five years. High and low ADCC titers were seen in all stages (except in Ho stage V), and the distribution of patients by high and low ADCC titers was similar in each of the stage groupings. We conclude that the ADCC titer at the time of diagnosis is generally predictive of the prognosis. Clinical staging is the traditional approach for predicting prognosis, but determination of the ADCC titer can be used to segregate patients within the stage groups into those with "good" and "poor" prognoses. Serologic testing may eventually become one of the methods for staging patients with WHO types 2 and 3 nasopharyngeal carcinoma.

(Arch Otolaryngol 1984;110:742-747)

Author Affiliations
From the Departments of Otorhinolaryngology (Dr Neel), Immunology (Dr Pearson), and Medical Statistics and Epidemiology (Dr Taylor), Mayo Clinic and Mayo Foundation, Rochester, Minn.

Footnotes
Accepted for publication June 18, 1984.

Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, May 10, 1984.

Reprint requests to Department of Otorhinolaryngology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Neel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Epstein-Barr Virus-Related Antibody: Changes in Titers After Therapy for Nasopharyngeal Carcinoma
Neel and Taylor
Arch Otolaryngol Head Neck Surg 1990;116:1287-1290.
ABSTRACT  

New Staging System for Nasopharyngeal Carcinoma: Long-term Outcome
Neel and Taylor
Arch Otolaryngol Head Neck Surg 1989;115:1293-1303.
ABSTRACT  

Enzyme-Linked Immunosorbent Assay of Antibodies to Epstein-Barr Virus Nuclear and Early Antigens in Patients with Infectious Mononucleosis and Nasopharyngeal Carcinoma
HALPRIN et al.
ANN INTERN MED 1986;104:331-337.
ABSTRACT